Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.

Interim positron emission tomography (PET) scan can be used to assess prognosis and risk-stratify patients.

中期正电子发射断层扫描（PET）可用于评估预后并根据风险对患者进行分层。

The prognostic value of interim PET was assessed in this post hoc exploratory analysis from ECHELON-2, evaluating interim 18F-fluorodeoxyglucose PET scans after cycle 4 (PET4) and end-of-treatment-based response, and correlated with PFS per investigator and OS.

本研究为ECHELON-2的事后探索性分析，评估了中期PET在预测预后中的价值，通过第4周期后的18F-氟脱氧葡萄糖PET扫描（PET4）和基于治疗结束时的反应，与研究者评估的无进展生存期（PFS）和总生存期（OS）相关联。

PET4 response was determined by Deauville score (scores of 1-3 were considered negative [PET4-negative] and 4-5 positive [PET4-positive]) by independent review.

PET4的反应由独立评审通过Deauville评分确定（1-3分被认为是阴性反应[PET4阴性]，4-5分被认为是阳性反应[PET4阳性]）。

Overall, 452 patients were randomized 1:1 to the BV-CHP (n = 226) and CHOP (n = 226) arms.

总体而言，452名患者按1:1的比例随机分配到BV-CHP组（n = 226）和CHOP组（n = 226）。

Of these, 32 in the BV-CHP arm and 41 in the CHOP arm were not evaluable for PET4.

在这些患者中，BV-CHP组有32名患者和CHOP组有41名患者无法评估PET4。

In both arms, PET4-negative status was associated with improved PFS (BV-CHP: HR, 0.36; 95% CI, 0.19-0.66; CHOP: HR, 0.26; 95% CI, 0.17-0.41) and OS (BV-CHP: HR, 0.38; 95% CI, 0.18-0.78; CHOP: HR, 0.24; 95% CI, 0.14-0.41) compared with PET4-positive status.

在两个治疗组中，PET4阴性状态与改善的无进展生存期（PFS）（BV-CHP：风险比，0.36；95%置信区间，0.19-0.66；CHOP：风险比，0.26；95%置信区间，0.17-0.41）和总生存期（OS）（BV-CHP：风险比，0.38；95%置信区间，0.18-0.78；CHOP：风险比，0.24；95%置信区间，0.14-0.41）相关，与PET4阳性状态相比。

Among patients with systemic anaplastic large cell lymphoma, PET4-negative patients had improved PFS (BV-CHP: HR, 0.28; 95% CI, 0.14-0.60; CHOP: HR, 0.31; 95% CI, 0.17-0.56) and OS (BV-CHP: HR, 0.38; 95% CI, 0.16-0.94; CHOP: HR, 0.25; 95% CI, 0.12-0.55) compared with PET4-positive patients.

在系统性间变性大细胞淋巴瘤患者中，与PET4阳性患者相比，PET4阴性患者的无进展生存期（PFS）（BV-CHP：风险比，0.28；95%置信区间，0.14-0.60；CHOP：风险比，0.31；95%置信区间，0.17-0.56）和总生存期（OS）（BV-CHP：风险比，0.38；95%置信区间，0.16-0.94；CHOP：风险比，0.25；95%置信区间，0.12-0.55）有所改善。

In this exploratory analysis, PET4-negative status by Deauville score was associated with improved long-term PFS and OS in both the BV-CHP and CHOP arms.

在这项探索性分析中，通过Deauville评分的PET4阴性状态与BV-CHP和CHOP方案组的长期无进展生存（PFS）和总生存（OS）改善相关。

This trial was registered at www.ClinicalTrials.gov as #NCT01777152.

这项试验已在www.ClinicalTrials.gov上注册，注册号为#NCT01777152。